Expert Review: Individualized Prostate Cancer Care in 2011 and Beyond |
This expert discussion utilizes clinical scenarios covering various stages of prostate cancer to address challenges in personalizing prostate cancer care, including identifying patients with prostate cancer using appropriate screening methods, individualizing care based on therapeutic profiles, and improving communication between the patient and physician and among a multidisciplinary care team. |
| Moderator |
 |
| |
Lee Lokey, MD
prIME Oncology
|
| Discussants |
| |
Maria José Ribal, MD
Hospital Clinic of Barcelona
Barcelona, Spain
|
| |
Steven Joniau, MD
University Hospital Leuven
Leuven, Belgium
|
| |
Thomas Wiegal, MD
University of Ulm Hospital
Ulm, Germany
|
|
Learning Objectives | After successful completion of this educational activity, participants should be able to:
- Describe recent progress in the treatment of prostate cancer and discuss the need to individualize management approaches to this disease
- Identify prostate cancer patient profiles and divide these profiles into localized, locally advanced, and metastatic disease
- Propose strategies for improving communication between patients and physicians
- Incorporate multidisciplinary treatment regimens into the care of patients with prostate cancer
|
 Disclosure of Conflicts of Interest | prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
|
Disclosure of Unlabeled Use | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
|
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Activity Date | This interview is available from 14 October 2011 to 14 October 2012. |
Audience | This educational activity is designed for urologists, medical oncologists, and radiation therapists active in the management of patients with prostate cancer. |
SPONSORSHIP | This interview is a prIME Oncology activity.
|
Support | Support for this educational activity is provided by Ipsen.
|
|